We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 8.20% | 3.30 | 2.60 | 4.00 | 0.00 | 16:35:17 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 6.78 | 9M |
From Apr 2019 to Apr 2024
TIDMPRM
RNS Number : 6479H
Proteome Sciences PLC
12 June 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company"
New Registered Address
Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London, and the Board has approved that from 12 June 2017 the new registered address will be Hamilton House, Mabledon Place, London, WC1H 9BB.
This office relocation marks the final step in the consolidation of company premises which also saw the integration of all laboratory capabilities in Frankfurt from 1 May 2017.
For further information: Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065 Dr Ian Pike, Chief Scientific Officer Geoff Ellis, Finance Director finnCap Limited (Nominated Adviser/Broker) Tel: +44 (0)20 7220 Geoff Nash/James Thompson 0500 Tony Quirke (broking) IFC Advisory (Financial PR and IR) Tim Metcalfe/Graham Tel: +44 (0)20 3053 Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAPKNEEFXEEF
(END) Dow Jones Newswires
June 12, 2017 02:00 ET (06:00 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
